China Unionpay Co., Ltd.

Chinese Academy of Sciences

Cilag International Gmbh

Qilu Regor Therapeutics Inc.

Other

Huawei Technologies Co., Limited

Alcatel Lucent

Ethicon, Gmbh

Shanghai United Imaging Healthcare Co., Ltd.

Delta Electronics (Shanghai) Co., Ltd

Pegatron Corporation

Protek (Shanghai) Limited

Shanghai Boc Chemical Co., Ltd.

Hangzhou Nuoyi Medtech Co., Ltd

Eastcompeace Smart Card Co., Ltd.

Wei Guo

Yu Chen Zhou

Shuo He

Zhijun Lu

Hongfeng Chai

Chengqian Chen

Dingzhou Li

Wenge Zhong

Patrick J Minnelli

Yachuan Yu

Chad Paul Boudreaux

Daniel J Mumaw

Kristen G Denzinger

Cheng Peng

Frederick E Shelton, IV

Jeffrey David Messerly

Craig N Faller

Wanqiang Zhang

Lixin Zhao

Timothy S Holland

Monica L Zeckel

Limin Zhang

Ryan M Asher

Bin Yu

Qiang Li

Hao Sun

Ming Chen

Yali Guo

Hongwen Meng

Xiangxiang Yan

Qinlin Gu

William A Olson

Joseph Daniel Dennis, Jr

Ellen E Burkart

Tyler N Brehm

James Anthony McCrea

Richard W Flaker

Jin Qian

Bryce Loring Heitman

Hao Liu

Monica L Rivard

Shih-Wei Hung

John Michael Sarley

Yongsheng Wang

Peiai You

Jintan Wu

Lan Xu

Michael A Keenan

Quan Sun

Jianbin Zheng

Lingfeng Lin

Zhaoyin Wang

Jianmin Li

Xiawei Jiang

Yu Zhou

Lianqing Liu

Wenhai Yu

Robert S Bishop

Yongshuai Chai

James A Mccrea

Junhua Zhu

Shulin Chen

Pengyuan Chen

Zheng Jane Li

Jidong Zhu

Shangli Li

Hailin Jing

Lin Cong

Hongzhou Chen

Ziming Chen

Demao Li

Kuo Hou

Zhongguo Zhou

Yunfeng Xu

Yunhua Wang

Pingbao Lv

Yuchu Ma

Zhongtao Zhang

Yuanyuan Zhou

Jun-Hua Shao

Guohao Jiang

Jiaming Qiu

Cheng-Jun Liu

Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

Crystal forms of GLP-1R agonists and uses thereof

The present disclosure provides intermediates used for preparing Brivaracetam, a preparation method and a use thereof, including an intermediate compound A and an intermediate compound B and a preparation method thereof, as well as a synthetic route for using the intermediate compound B to prepare Brivaracetam. The present technical solution can obtain high-quality and high-optical purity Brivaracetam and intermediates thereof, the proportion of Brivaracetam among the four optical isomers being greater than 99.5%. In addition, neither silica gel column for separation and purification nor expensive chiral high performance liquid chromatography for resolution is required, thereby avoiding cumbersome separation and purification steps, also avoiding waste of raw materials, reducing the production cost and making it more suitable for industrial production.

Intermediate compounds used for preparing brivaracetam, preparation methods for intermediate compounds, and use

The present application discloses a payment information processing method, apparatus, device, and computer readable storage medium. The payment information processing method includes: obtaining an environment image collected by a mobile acquiring device, in response to an acquiring request sent by the mobile acquiring device; determining a payment environment confidence level of the mobile acquiring device according to the environment image, under a condition that the mobile acquiring device obtains payment card information; determining a payment information processing result according to the payment environment confidence level.

Payment information processing method, apparatus, device and computer readable storage medium

An end-effector is disclosed. The end-effector includes a clamp arm and an ultrasonic blade configured to acoustically couple to an ultrasonic transducer and electrically couple to a pole of an electrical generator. The clamp arm includes a clamp jaw, a clamp arm pad, and a cantilever electrode that is free to deflect. The cantilever electrode is configured to electrically couple to an opposite pole of the electrical generator. Also disclosed are configurations where the clamp arm includes a peripheral cantilever electrode and a clamp arm pad extending beyond the electrode, a floating cantilever electrode and a resilient clamp arm pad, an interlocked cantilever electrode plate and a clamp arm pad configured to receive the plate, a laterally deflectable cantilever electrode and a clamp arm pad extending beyond the electrode, and a flexible cantilever electrode and a clamp arm pad extending beyond the electrode.

Deflectable support of RF energy electrode with respect to opposing ultrasonic blade

A non-contact communication method and a communication device are presented. The communication device includes a trusted execution environment (TEE). A first security application and a second security application are provided in a security element of the communication device. The first security application and an application in the trusted execution environment are communicationally connected by means of a first communication channel. The second security application and a near-field communication (NFC) module provided in the communication device are communicationally connected by means of a second communication channel. The first security application and the second security application are communicationally connected by means of a security channel. Using the non-contact communication method and the communication device, a security channel may be established between NFC and a TEE, which may enable NFC non-contact card reading for a TEE application.

Non-contact communication method and communication device

A surgical instrument has an ultrasonic blade that connects to a distal end of an ultrasonic waveguide. A clamp arm assembly is moveable from an opened position for receiving a tissue, toward a closed position for clamping the tissue. A clamp arm actuator connected to the clamp arm assembly directs the clamp arm assembly from the opened position toward the closed position. An outer sheath surrounds at least a portion of the ultrasonic waveguide. The outer sheath includes a cover removably received against a sheath body, and a sheath securement feature able to detachably couple the cover to the sheath body such that the cover can be detached from the sheath body for accessing the ultrasonic waveguide within the outer sheath.

Surgical instrument with removable portion to facilitate cleaning

A deformable segment with combined motion includes a flexible center backbone, the tendons of deformable segment with combined motion, a connecting piece, a proximal disk and a distal disk. The proximal end of the flexible center backbone and the proximal ends of the tendons of deformable segment with combined motion are fixedly connected to the proximal disk. The distal ends of the tendons of deformable segment with combined motion are fixedly connected to the distal disk. The distal end of the flexible center backbone penetrates through the distal disk and then extends into the distal execution segment, and is connected with the end-effector. The deformable segment with combined motion is provided with the connecting piece. The proximal driving segment is provided with proximal driving tendons. The proximal driving tendons penetrate through the proximal disk, and then are fixedly connected with the connecting piece.

Deformable mechanism with combined motion

The present disclosure provides compounds of Formula (III) 

GLP-1R agonists and uses thereof

The present invention relates to a method for access control of a multimedia system to a secure operating system and a mobile terminal for implementing the method. The method includes the steps of: initiating an application access request for selecting a trusted application from a client application of a multimedia system to a secure operating system; making a decision as to whether the client application is a malicious application, and if not, proceeding to a next step, if yes, returning Selection Failure to the client application and performing an interrupt handling; sending the application access request from the multimedia system to the secure system; and acquiring, at the secure operating system, the trusted application based on the application access request and returning the trusted application to the multimedia system. The malicious accesses initiated by a malicious application to a trusted application in a securing operating system can be prevented without switching between systems, and the problem that a trusted application cannot be accessed due to malicious access can be avoided.

Tee access control method and mobile terminal implementing same

A venous valve replacement device includes a stent with a blood flow channel and two leaflets connected to the stent, wherein one side of each leaflet is configured as a fixed edge connected with the stent, and the other side is configured as a movable edge, and wherein the movable edges of the two leaflets cooperates with each other to open or close the blood flow channel, and the movable edges of the two leaflets are provided with flaps that attach to each other in a closed configuration.

Venous valve replacement device

Embodiments of the present invention disclose an application management method for terminals, including: after receiving the application download request sent by the terminal, the application server sends the corresponding application installation package to the terminal. Then, the first verification message sent by the terminal is received, and the first verification message is generated by the terminal according to the content of the received application installation package. After determining that the first verification message is consistent with a stored second verification message, the application server sends an permit-to-install message to the terminal, so that the terminal installs the application according to the received application installation package. Because the application server determines the legitimacy of the application package, it does not need the terminal to verify by using the certificate, thereby reducing the certificate work management for the terminal and improving the efficiency of application installation.

Application management method for terminal, application server, and terminal

The present disclosure relates to user plane link establishment methods. One example method includes sending, by a first base station, an obtaining request associated with user equipment to a second base station, receiving, by the first base station, a response message corresponding to the obtaining request, where the response message includes a peer address associated with the user equipment, and establishing, by the first base station and based on the peer address, a user plane link corresponding to the user equipment.

User plane link establishment method, base station, and mobility management device

A surgical instrument has a first modular assembly and a second modular assembly. The first modular assembly has a body, an ultrasonic waveguide, an ultrasonic blade connected to a distal end of the ultrasonic waveguide, and a coupling member that movably couples with the body. The second modular assembly has a clamp arm assembly with a first pivot coupling, a clamp pad assembly with a second pivot coupling, and a distal outer sheath that selectively couples to the body of the first modular assembly via the coupling member. The distal outer sheath has an interior surface that houses a portion of the ultrasonic waveguide, and this interior surface also houses the first pivot coupling and the second pivot coupling.

Surgical instrument with removable clamp arm assembly

Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases. 

Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor

The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

Growing community of inventors

Shanghai, China

Wei Guo